Bio-Path Holdings

Webcast Link to Third Quarter 2023 Financial Results Conference Call on Wednesday, November 15, 2023 at 8:30 a.m. ET

Bio-Path announced a repositioning to support growth, added scientific advisors, engaged bankers, and canceled a reverse split.

Webcast link to Corporate Update Conference Call on Thursday, May 29, 2025 at 8:30 a.m. ET

Bio-Path is a biotechnology company focused on clinical development of therapeutics using DNAbilize, its patented method for producing antisense DNA therapeutics for indications including cancer.

Vik Grover was named Bio-Path Holdings chairman and CEO in October 2025 to pursue a turnaround and reengage its Phase 1 and Phase 2 trials. He is also CEO of Himalaya Technologies and Everest Networks and an independent investment banker.

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other cancers.

Bio-Path seeks to apply DNAbilize, its neutral-lipid delivery technology, to new protein targets in cancer and other diseases. It is interested in co-development and sublicensing arrangements for liposomal antisense drug candidates.

Bio-Path Holdings, Inc. lists its address as 625 Stanwix Street, Pittsburgh, PA 15222, and its phone number as (630) 708-0750.

Bio-Path says it is developing targeted cancer treatments without harsh side effects to provide tolerable treatment options for fragile patients. The page says the prognosis for fragile cancer patients remains very poor.

The page lists biopath.wpengine.com as its website and says it collects comment-form data, IP addresses, and browser user-agent strings to help detect spam.

this page intentionally left blank